Scilex Holding Company - Common Stock (SCLX)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Piotroski F-Score 4/9 — moderate financial health
- Loss-making — negative ROE of -253,786.6%
- Revenue declining 47% annually
Scilex Holding Company - Common Stock (SCLX) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $64 million . Key value metrics: Piotroski F-Score 4 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Scilex Holding Company - Common Stock — Fundamental Analysis Summary
On financial health, SCLX shows a moderate Piotroski F-Score of 4/9, and negative return on equity of -253,786.6% (sector average: -20.6%).
StockPik's composite Value Score for SCLX is 45/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SCLX reports a high gross margin of 90.9% (sector average: 39.4%) and a negative operating margin of -783.9%.
SCLX shows revenue declining at 47% year-over-year, with earnings declining at 414%.